We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Liquid Bioassay for Ultrasensitive Detection of Circulating HPV DNA

By LabMedica International staff writers
Posted on 04 Oct 2021
Print article
Image: The HPV-Seq test is an ultra-sensitive liquid biopsy solution for the identification and quantification of circulating HPV 16 and HPV 18 DNA in patients with cancers caused by HPV infection (Photo courtesy of Sysmex Inostics)
Image: The HPV-Seq test is an ultra-sensitive liquid biopsy solution for the identification and quantification of circulating HPV 16 and HPV 18 DNA in patients with cancers caused by HPV infection (Photo courtesy of Sysmex Inostics)
A recent paper concluded that for cancers caused by the human papillomavirus (HPV), the HPV-seq technique was a promising ultrasensitive approach for detection and analysis of circulating tumor DNA (ctDNA).

HPV DNA offers a convenient ctDNA marker for HPV-associated cancers, but current methods such as digital PCR (dPCR) provide insufficient accuracy for clinical applications in patients with low-disease burden. In this light, investigators at Princess Margaret Cancer Centre (Toronto, Canada) asked whether a next-generation sequencing approach (HPV-seq) could provide quantitative and qualitative assessment of HPV ctDNA in low-disease-burden settings.

The classical PCR test carries out one reaction per single sample. The digital PCR (dPCR) method also carries out a single reaction within a sample, however the sample is separated into a large number of partitions and the reaction is carried out in each partition individually. This separation allows a more reliable collection and sensitive measurement of nucleic acid amounts. The dPCR method has been demonstrated as useful for studying variations in gene sequences - such as copy number variants and point mutations - and it is routinely used for clonal amplification of samples for next-generation sequencing.

The HPV-seq test is an ultra-sensitive liquid biopsy approach for the identification and quantification of circulating HPV 16 and HPV 18 DNA in patients with cancers caused by HPV infection, including cervical cancer, anal squamous cell carcinoma, and head and neck squamous cell cancer. HPV-seq detects cell-free HPV DNA across a large dynamic range and demonstrates accurate quantification even when few copies are present, enabling high-resolution molecular monitoring.

For the current study, the investigators conducted pre-clinical technical validation studies on HPV-seq and applied it retrospectively to a prospective multicenter cohort of locally-advanced cervix cancer patients and a cohort of oropharynx cancer patients. HPV-seq results were compared with those obtained by dPCR.

Results revealed that HPV-seq achieved reproducible detection of circulating HPV DNA at levels that were up to 20-fold lower than those detectable by dPCR. Detectable HPV ctDNA at end-of-treatment was associated with inferior progression free survival with 100% sensitivity and 67% specificity for recurrence. Accurate HPV genotyping was successful from 100% of the pre-treatment samples.

"Increasingly, as clinicians we are focused on precision medicine and making sure we are not over-treating people while still curing them. That is a very difficult balance to strike," said senior author Dr. Scott Bratman, assistant professor of radiation oncology and medical biophysics at Princess Margaret Cancer Centre. "We are really at the cusp of a revolution from a technology, clinical implementation, and standard of care standpoint, where five to 10 years from now we will not be treating everybody with the same dose of radiation and chemotherapy, and then waiting months to see if the treatment was effective. I am confident we will be giving much more tailored doses. Patients who need more treatment will then be able to continue on, or different treatments can be added. We can spare the vast majority of patients who will not need those interventions and provide them with a greater quality of life once they are cured of the cancer."

The HVP DNA bioassay paper was published in the September 27, 2021, online edition of the journal Clinical Cancer Research.

Related Links:
Princess Margaret Cancer Centre

New
Gold Supplier
Fully Automated ELISA Workstation
EUROLabWorkstation ELISA
New
Lateral Flow Test Cassette Reader
Quantum Blue III
New
Cytology Sample Processor
SDSCP9000 CytoPath Processor
New
Bulk Sorter
BL 1200 SORT CONNECT

Print article

Channels

Hematology

view channel
Image: The Gazelle Hb Variant Test for screening, diagnosis and management of sickle cell disease and related hemoglobinopathies at the point of care (Photo courtesy of Hemex Health)

Point-of-Care Device Accurately Rapidly Diagnoses Sickle Cell Disease

Hemoglobinopathies are the most common autosomal hereditary disorders. Approximately 7% of the global population carries hemoglobin gene mutation including structural hemoglobin variants like sickle hemoglobin... Read more

Immunology

view channel
Image: The IMMULITE 2000 XPi Immunoassay System provides multiple tests on a single, easy-to-use analyzer, including the thyroid-stimulating immunoglobulin assay (Photo courtesy of Siemens Healthcare)

Immunoassays Evaluated for Thyroid-Stimulating Receptor Antibody in Graves’ Disease

Graves' disease (GD), also known as toxic diffuse goiter, is an autoimmune disease that affects the thyroid. It frequently results in and is the most common cause of hyperthyroidism and it also often results... Read more

Microbiology

view channel
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated... Read more

Pathology

view channel
Illustration

AI Accurately Detects and Diagnoses Colorectal Cancer from Tissue Scans As Well or Better Than Pathologists

Artificial intelligence (A) can accurately detect and diagnose colorectal cancer from tissue scans as well or better than pathologists, according to a new study. The study, which was conducted by researchers... Read more

Technology

view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more

Industry

view channel
Illustration

Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases

The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.